Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
News|Articles|December 2, 2003
- Pharmaceutical Technology-12-02-2003
- Volume 27
- Issue 12
All Signs Indicate a Strong 2004 for Contract Services
Author(s)Jim Miller
Exhibitors at October's AAPS meeting confirmed that the demand for services is robust and believe that the industry's pipeline appears stronger than it has been in the past few years.
Advertisement
Articles in this issue
almost 23 years ago
December 2003almost 23 years ago
Behavior of Uptake of Moisture by Drugs and Excipientsalmost 23 years ago
Targeted Cationic Liposomes, Technologies, and Developmentsalmost 23 years ago
Sixth Annual International Employment Survey: Staying the Coursealmost 23 years ago
Drug Pricing Concerns Shape Policy Decisions in 2003almost 23 years ago
In the Spotlight--January 2004almost 23 years ago
December 2003Advertisement
Related to this article
Shilpa Pharma Lifesciences Limited will launch a new small-molecule CDMO at CPHI Milan in October.
This article explains the 4 shifts enabling faster, lower-risk, commercially successful biologics technology transfer.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pharma Fundamentals: Digital Pathology in Drug Development, Part 1
2
PharmTech’s Weekly Roundup—September 25, 2026
3
EU Clears AstraZeneca's Trixeo for Asthma, Opening New Manufacturing Demand for Single-Inhaler Triple Therapy
4
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
5